Skip to content

The effect of Remifentanil and Apotel in pain control of patients undergoing laparotomy

Comparison of the effect of remifentanil and apotel on pain control of laparotomy using a pain pump

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20191104045328N24
Enrollment
70
Registered
2024-08-21
Start date
2024-08-26
Completion date
Unknown
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain. Acute pain, not elsewhere classified

Interventions

Intervention 1: Intervention group: In this group, a pain pump containing 100 cc of normal saline and 0.5 micrograms/kg of Remifentanil 2mg manufactured by Elixir Company of Iran will be installed in

Sponsors

Arak University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Candidates for emergency laparotomy include cancer of abdominal organs, peritonitis, appendicitis, pancreatitis, abscess, adhesions (after trauma or surgery), diverticulitis, intestinal perforation or obstruction, foreign bodies and internal bleeding in accessible spaces. Aged 18 to 65 years Consent of the participants to participate in the study

Exclusion criteria

Exclusion criteria: Addiction to any drug Known hypersensitivity to remifentanil or Apotel Complicated laparotomy Laparotomy with long unconventional time Wound infection

Design outcomes

Primary

MeasureTime frame
Intensity of pain. Timepoint: Immediately after consciousness, 1 hour later, 3 hours later, 8 hours later and finally 24 hours after surgery. Method of measurement: Visual analog scale.;Taking additional painkillers. Timepoint: Within 24 hours after surgery. Method of measurement: History.;Side effects. Timepoint: during operation. Method of measurement: History.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Alireza Kamali

Arak University of Medical Sciences

alikamaliir@yahoo.com+98 38 4817 6941

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026